FDA Seeks Public Comment on Information Collection by Radioactive Drug Research Committees
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
The FDA is requesting public comments on the data collection process regarding the use of radioactive drugs in basic research. The goal is to ensure that research protocols adhere to regulations and that human subjects are protected during studies. Stakeholders such as researchers, committee members, and study participants will be impacted by these requirements, which include annual reporting and safety assessments.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- FDA collects public feedback on data collection for radioactive drug use in research.
- Research protocols involving radioactive drugs need approval and oversight by FDA-approved committees.
- Annual reporting and adverse event communication are required from committees.
Obligations
What this law requires
Each Radioactive Drug Research Committee (RDRC) must select a chairman who will sign all applications, minutes, and reports of the committee.
Each Radioactive Drug Research Committee (RDRC) must select a chairman who will sign all applications, minutes, and reports of the committee.
Each RDRC is required to meet at least once each quarter during which research activity has been authorized or conducted.
Each RDRC is required to meet at least once each quarter in which research activity has been authorized or conducted.
Each RDRC must submit an annual report to the FDA that includes the names and qualifications of members and any consultants, using Form FDA 2914.